Global Osteoporosis Drugs Market is Expected to Reach at a CAGR of 5.53% from 2018 to 2025

A new research report published by Fior Markets with the title Osteoporosis Drugs Market by Drug Class (Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), Parathyroid Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, Branded, Generics, Others), Gender, Route of Administration (Oral, Injectable, Others), Region and Global Forecast 2018-2025.

As per the report, the global osteoporosis drugs market is expected to grow from USD 1,434.17 Billion in 2017 to USD 1,816.27 Billion by 2025 at a CAGR of 5.53% during the forecast period from 2018-2025. The presence of well-established medical & healthcare infrastructure, substantial investments in the healthcare activities, favorable R& D policies of the government towards the osteoporosis drug applications are the major trends for the increasing osteoporosis drugs market in North America region.

DOWNLOAD FREE SAMPLE REPORT: https://www.fiormarkets.com/report-detail/386032/request-sample

Prominent companies in the industry include Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche, Teva Pharmaceutical Industries, Ltd., GlaxoSmithKline plc, Novartis International AG, Merck & Co. Inc., Amgen Inc, Radius Health, Inc., Novo Nordisk A/S, Actavis plc, GlaxoSmithKline plc, and among others are offering greater opportunities and major players are continuously focused on new product developments and venture capital investments to obtain market share. For instance, in 2018, linigen Group PLC acquired the global rights to osteoporosis drug Imukin from Horizon Pharma PLC. Horizon will retain the rights to Actimmune, a similar drug, in the US, Canada and Japan.

Drug class segment includes bisphosphonates, selective estrogen inhibitors modulator (SERM), parathyroid hormone therapy, calcitonin, rank ligand inhibitors, generics, and others. The bisphosphonates segment held highest market share of 31.08% in 2017. Bisphosphonates are the most commonly prescribed medication for treatment and prevention of osteoporosis. Route of administration segment covers oral, injectable, and others. The oral segment valued around USD 805.72 million in 2017 owing to high preference of oral osteoporosis drugs, ease of availability, and is commonly prescribed medication for treatment. Gender segment consist of male and female. The female segment is anticipated to grow with highest CAGR 6.29% during the forecast period owing to increasing the risk of fractures, mainly in wrist, hip, and spinal vertebrae are seen more in women’s over the age of 50. According to International Osteoporosis Foundation (IOF), the number of women suffering from osteoporosis has crossed more than 200 million globally.

Increasing geriatric population, changing lifestyles impinging bone health, increasing the prevalence of osteoporosis in postmenopausal women are the key driving factors for the osteoporosis drugs market. In addition, growing awareness about osteoporotic care, and increasing investment in drug discovery and development will lead the growth of osteoporosis drugs market in couple of years. The side effects of osteoporosis drugs and patent expiration of osteoporosis drug may limit the growth of market. However, increasing R&D investment in drug discovery and development and increasing healthcare expenditure is expected to boost the osteoporosis drugs market over the forecast period.

ACCESS FULL REPORT: https://www.fiormarkets.com/report/osteoporosis-drugs-market-by-drug-class-bisphosphonates-selective-386032.html

About the report: 
The global osteoporosis drugs market is analysed on the basis of value (USD Billion), volume (K Units), export (K Units), and import (K Units). All the segments have been analyzed on global, regional and country basis. The study includes the analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porter’s five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.

Customization of the Report:
The report can be customized as per client requirements. For further queries, you can contact us on sales@fiormarkets.com or +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

Contact Us
Mark Stone
Phone: +1-201-465-4211
Email: sales@fiormarkets.com
Web: www.fiormarkets.com

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.